谷博實(shí)業(yè)

優(yōu)勢(shì)供應(yīng)，正品保證，*

全國(guó)：

在線咨詢

ENZO公司 代理

瑞士Enzo Life Sciences

： www.enzolifesciences.com www.enzo.com

Enzo Biochem Inc：（NYSE:ENZ）

這是一家致力于主要遺傳學(xué)過(guò)程的研究工具，診斷，治療和相關(guān)醫(yī)學(xué)團(tuán)體實(shí)驗(yàn)室服務(wù)的ling命科學(xué)與生物技術(shù)公司。成立于1976年，集中于基因調(diào)控和基因修飾等方面的工具方法發(fā)展。

Enzo Biochem, Inc. （Enzo） is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company also operates a clinical laboratory that offers and provides diagnostic medical testing services to the health care community in the New York Metropolitan and New Jersey areas. The Company operates in three segments: Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. On May 8, 2008, Enzo Life Sciences, Inc., a wholly owned subsidiary of the Company, acquired all of the United States-based assets of Biomol International, LP （Biomol） and its wholly owned United Kingdom subsidiary, Affinity Limited.

ENZO® - A Brand of Enzo Life Sciences, Inc.

Innovative Labeling and Detection™

Enzo® is a recognized leader in labeling and detection technologies across research and diagnostic markets. A strong portfolio of labeling probes and dyes provides life science environments tools for target identification/validation and high content analysis via gene expression analysis, nucleic acid detection, protein biochemistry and detection, and molecular and cellular biology.

Enzo Life Sciences 

Enzon 

 美國(guó)Enzon Pharmaceuticals, Inc. www.enzon.com

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon’s PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company’s revenue base.